干血斑CK-MM免疫分析法用于杜氏肌营养不良新生儿筛查的表征
该研究在PerkinElmer GSP分析仪上开发了自动化双位点免疫荧光法检测干血斑中的CK-MM同工酶,用于杜氏肌营养不良新生儿筛查。方法学评价显示空白限<1 ng/mL、检测限3 ng/mL、定量限8 ng/mL,分析测量范围4-8840 ng/mL,批间不精密度<7%。277例新生儿干血斑CK-MM均值155 ng/mL,99百分位563 ng/mL;10例DMD患儿均值5458 ng/mL(范围1217-9917 ng/mL)。
要点
- 干血斑CK-MM免疫分析法可可靠定量,分析性能满足高通量新生儿筛查需求。
- 新生儿干血斑CK-MM 99百分位为563 ng/mL,DMD患儿均值5458 ng/mL。
- 该方法对CK-MB交叉反应<5%,对CK-BB交叉反应为0%。
核心结论
- CK-MM可在干血斑中可靠定量,在商品化免疫分析仪上开发该检测可实现标准化、高通量的DMD新生儿干血斑筛查。
研究设计与样本
- 在PerkinElmer GSP分析仪上开发原型检测方法,采用固相双位点免疫荧光系统检测CK-MM,以纯化人CK-MM制备校准品和质控品。
主要发现
- 空白限<1 ng/mL,检测限3 ng/mL,定量限8 ng/mL,分析测量范围4-8840 ng/mL。
- 批间不精密度(n=40)在全分析范围内<7%。
- 对CK-MB交叉反应<5%,对CK-BB交叉反应为0%。
- CK-MM平均回收率为101%(范围87%-111%)。
- 277例新生儿干血斑CK-MM均值为155 ng/mL,99百分位为563 ng/mL;10例DMD患儿干血斑CK-MM均值为5458 ng/mL(范围1217-9917 ng/mL)。
关键数值与推荐
- 干血斑CK-MM检测的空白限<1 ng/mL、检测限3 ng/mL、定量限8 ng/mL。
- 分析测量范围4-8840 ng/mL,批间不精密度<7%。
- 新生儿干血斑CK-MM 99百分位为563 ng/mL,DMD患儿均值为5458 ng/mL(范围1217-9917 ng/mL)。
临床怎么用
- 该CK-MM免疫分析法可用于新生儿干血斑DMD筛查,在商品化免疫分析仪上实现标准化高通量检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive, lethal X-linked neuromuscular disorder with an average worldwide incidence of 1:5000. Blood spot creatine kinase (CK) enzyme assays previously used in newborn screening programs for DMD are nonspecific because measured CK enzyme activity is attributable to 3 isoenzyme forms of CK (CK-MM, CK-MB, and CK-BB) and it is the CK-MM isoform that is found predominantly in skeletal muscle. CK-MM is increased in boys with DMD owing to muscle damage. We describe a sensitive and specific automated immunoassay for CK-MM to screen for DMD in blood spots. METHODS: The prototype assay was developed on the PerkinElmer GSP® analyzer to enable high-throughput screening. CK-MM was assayed using a solid phase, 2-site immunofluorometric system. Purified human CK-MM was used to create calibrators and controls. RESULTS: The limit of blank (LOB), detection (LOD), and quantification (LOQ) values were <1, 3, and 8 ng/mL, respectively. The analytical measurement range was 4-8840 ng/mL. Interassay (n = 40) imprecision was <7% across the analytical range. Cross-reactivity was <5% for CK-MB and 0% for CK-BB. The mean recovery of CK-MM was 101% (range 87%-111%). Blood spots from newborn infants (n = 277) had a mean CK-MM concentration of 155 ng/mL and a 99th centile of 563 ng/mL. The mean blood spot CK-MM concentration from 10 cases of DMD was 5458 ng/mL (range 1217-9917 ng/mL). CONCLUSIONS: CK-MM can be reliably quantified in blood spots. The development of this CK-MM assay on a commercial immunoassay analyzer would enable standardized and high-throughput newborn blood spot screening of DMD.
引用
- Moat SJ, Korpimäki T, Furu P, et al. Characterization of a Blood Spot Creatine Kinase Skeletal Muscle Isoform Immunoassay for High-Throughput Newborn Screening of Duchenne Muscular Dystrophy. Clin Chem. 2017. PMID: 28209627. doi:10.1373/clinchem.2016.268425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。